REGN5668

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals

Conditions

Endometrial CancerFallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer

Phase 1

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

RecruitingNCT04590326

Regeneron PharmaceuticalsEndometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer +1

Start: 2020-12-08End: 2027-11-30Target: 612Updated: 2025-11-21

A PHASE 1/2 STUDY OF REGN5668 (MUC16 × CD28, A COSTIMULATORY BISPECIFIC ANTIBODY) ADMINISTERED IN COMBINATION WITH OTHER AGENTS IN MUC16+ MALIGNANCIES

RecruitingCTIS2022-501904-83-00

Regeneron Pharmaceuticals Inc.Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer

Start: 2023-09-11Target: 208Updated: 2025-12-03

Related Papers

A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA).

Journal of Clinical Oncology2021-05-205 citations